US 2022/0088231 A1 · RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY

Abstract

Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.

Dependent claims

A method for treating or ameliorating cancer, said method comprising:

(i) administering to a mammal a radioimmunoconjugate, wherein the mammal has received or is receiving a DNA damage response inhibitor (DDRi);
(ii) administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate;
or
(iii) administering to the mammal a DDRi at the same time as administering the mammal a radioimmunoconjugate.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

16/619,433Filed 3 Dec 2019

Priority

3 Dec 2018

Published

24 Mar 2022

Term ends

Not estimatedThe source records don’t support an estimate.

A61K 51/1036
Against receptors, cell-surface antigens or cell-surface determinants: against hormone receptors
A61K 31/502
Pyridazines; Hydrogenated pyridazines: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.

Dependent claims

A method for treating or ameliorating cancer, said method comprising:

(i) administering to a mammal a radioimmunoconjugate, wherein the mammal has received or is receiving a DNA damage response inhibitor (DDRi);
(ii) administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate;
or
(iii) administering to the mammal a DDRi at the same time as administering the mammal a radioimmunoconjugate.

1 more element

Dependencies are inferred from the claim text.